Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This communication reports previously unreported side effects, severe bullous dermatosis and onycholysis, in three patients undergoing high-dose methotrexate and leucovorin calcium therapy, impacting their chemotherapy schedules.

This study found that 65.2% of female pattern hair loss patients showed significant hair growth improvement with a daily dosage of 2.5 mg finasteride, with better outcomes in patients with lower initial Ludwig scores and older age at onset.

This study found that phototoxic psoralen and ultraviolet A therapy with topical 8-MOP was effective in treating alopecia areata resistant to other treatments, improving hair regrowth with minimal side effects.

This study found that in young male rats, cortisone acetate inhibited body growth and caused alopecia, which vitamin B12 and aureomycin largely counteracted, especially when combined.

This study reports serious adverse effects resulting from compounding errors when using low-dose oral minoxidil to treat alopecia.

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

This study aimed to assess whether using minoxidil alongside nutritional cyclical supplements could boost hair regrowth without antiandrogens or enzyme blockers, focusing on hair root strengthening. Results are not reported.

This review discusses the emerging evidence for low-dose oral minoxidil in treating various types of alopecia, without providing new clinical results.

This study found no significant difference in the persistence of new symptoms or quality of life improvements with 200,000 IU of vitamin D3 compared to placebo in patients post-COVID-19 hospitalization.

In this experimental study, researchers found that intravitreal injections of up to 100μg of topotecan in rabbits caused no systemic or ocular toxicity, while 200μg doses resulted in localized retinal changes and decreased electroretinography amplitudes near the injection site.

This article discusses the off-label use of low-dose oral minoxidil for alopecia and reports no new clinical findings, noting its presumed mechanism is enhancing hair follicle microcirculation with minimal blood pressure effects.

This study investigated the safety and efficacy of IV iron maltoside 1000 in treating iron-deficiency anemia among children with IBD and found a significant increase in hemoglobin levels by 6 weeks, maintained for up to a year, with minimal side effects reported.

This study suggests that using nutrient antioxidants can significantly reduce the dose of prednisolone needed in alopecia areata patients while potentially enhancing hair growth and mitigating side effects.

This case report describes a 23-year-old man experiencing painful gynecomastia aggravated by low dose finasteride for androgenetic alopecia, which reversed after stopping the medication.

This article discusses the availability of data from TriNetX for research purposes and reports no new findings.

In this case report, a 27-year-old woman experienced severe multisystem toxicity, including toxic encephalopathy, vision, and hearing loss, after ingesting selenium at occupationally high doses, suggesting such exposure can lead to previously unreported effects of vision and hearing impairment.

This case report highlights significant hair regrowth in a Malaysian woman with localized alopecia areata after intralesional triamcinolone acetonide treatment at a concentration of 5 mg/mL.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that oral minoxidil was associated with short-term improvements in clinical severity for androgenetic alopecia, whereas oral dutasteride did not show significant early clinical changes in the six-month follow-up.

In this retrospective study, researchers found that while combination therapy of spironolactone and oral minoxidil for female alopecia commonly led to mild outpatient-manageable side effects, starting both medications simultaneously reduced hypertrichosis risk, but taking multiple blood pressure medications increased hypotensive symptoms.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

This study found that naringin, a natural flavonoid, significantly improved hair growth in mice by activating the Wnt/β-catenin pathway, with the 4% concentration showing comparable efficacy to 5% minoxidil, suggesting naringin as a promising alternative for alopecia treatment.

This analysis reports no significant differences between spironolactone and metformin for managing PCOS, noting spironolactone remains a potential off-label option for patients unable to use hormonal contraceptives, but larger studies are necessary to confirm its efficacy.

This case report identified a possible adverse effect of low-dose oral minoxidil for female pattern hair loss, as a 74-year-old woman developed significant dry mouth that resolved after stopping the medication and recurred upon rechallenge, suggesting a causal link.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

In this study, female rats given high doses of testosterone showed decreased endometrial thickness and lower mRNA levels of components in the LIF signalling pathway, indicating that excessive testosterone may negatively impact endometrial receptivity and potentially affect fertility.